{
    "relation": [
        [
            "",
            "Total Study Population",
            "Capsule Formulation",
            "Tablet Formulation"
        ],
        [
            "Description",
            "HIV-1 infected participants who received any formulation of lopinavir/ritonavir during Parts I or II of the study (including 66 participants who received both tablet and capsule formulations, or oral solution).",
            "Participants who received the capsule formulation (only) of lopinavir/ritonavir during Part I or Part II of the study.",
            "Participants who received the tablet formulation (only) of lopinavir/ritonavir during Parts I or II of the study."
        ]
    ],
    "pageTitle": "Multicountry, Multicenter Post-Marketing Observational Study of Clinical, Biological and Virological Outcomes, Compliance and Tolerability of Kaletra\u00ae in Routine Clinical Use - Study Results - ClinicalTrials.gov",
    "title": "",
    "url": "https://clinicaltrials.gov/ct2/show/results/NCT01379703?sect=Xi0156&view=results",
    "hasHeader": true,
    "headerPosition": "MIXED",
    "tableType": "RELATION",
    "tableNum": 25,
    "s3Link": "common-crawl/crawl-data/CC-MAIN-2015-32/segments/1438042987135.9/warc/CC-MAIN-20150728002307-00310-ip-10-236-191-2.ec2.internal.warc.gz",
    "recordEndOffset": 861077115,
    "recordOffset": 861063051,
    "tableOrientation": "HORIZONTAL",
    "textBeforeTable": "Reporting Groups No text entered. Significant events and approaches for the overall study following participant enrollment, but prior to group assignment Pre-Assignment Details The study was carried out in two parts. The first part was initiated in 2004 with the lopinavir/ritonavir capsule formulation (Part I) and the second part (Part II) started in 2006 after the tablet formulation became available in participating countries. Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations Recruitment Details \u00a0 Hide Participant Flow \u00a0 Participant Flow HIV-1 Patients Condition: Time\u00a0Perspective:\u00a0Prospective Study Design: Observational Study Type: Results First Received: August 9, 2011 \u00a0",
    "textAfterTable": "Participant Flow for 2 periods Period 1: \u00a0 Study Start Through 9 Months \u00a0 \u00a0 Tablets and Capsules or Oral Solution \u00a0 \u00a0 Capsule Formulation \u00a0 \u00a0 Tablet Formulation \u00a0 STARTED \u00a0 \u00a0 66 [1] \u00a0 1206 [2] \u00a0 1016 [3] COMPLETED \u00a0 \u00a0 62 \u00a0 \u00a0 1084 [4] \u00a0 873 \u00a0 NOT COMPLETED \u00a0 \u00a0 4 \u00a0 \u00a0 122 \u00a0 \u00a0 143 \u00a0 Lost to Follow-up \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 2 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 61 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 104 \u00a0",
    "hasKeyColumn": true,
    "keyColumnIndex": 0,
    "headerRowIndex": 0
}